- Home
- SGC vs LUNG Comparison
SGC vs LUNG Comparison
Compare SGC & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SGC | LUNG |
|---|---|---|
| Founded | 1920 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Industrial Specialties |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 156.7M | 63.6M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | SGC | LUNG |
|---|---|---|
| Price | $10.05 | $2.54 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $17.33 | $6.81 |
| AVG Volume (30 Days) | 64.8K | ★ 1.1M |
| Earning Date | 11-03-2025 | 11-12-2025 |
| Dividend Yield | ★ 5.57% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | ★ $565,017,000.00 | $91,664,000.00 |
| Revenue This Year | $1.07 | $9.21 |
| Revenue Next Year | $3.03 | $5.03 |
| P/E Ratio | $27.84 | ★ N/A |
| Revenue Growth | N/A | ★ 15.59 |
| 52 Week Low | $8.30 | $1.31 |
| 52 Week High | $17.40 | $9.37 |
Technical Indicators
Market Signals| Indicator | SGC | LUNG |
|---|---|---|
| Relative Strength Index (RSI) | 59.30 | 71.32 |
| Support Level | $9.65 | $1.96 |
| Resistance Level | $10.44 | $1.74 |
| Average True Range (ATR) | 0.39 | 0.20 |
| MACD | 0.11 | 0.10 |
| Stochastic Oscillator | 83.23 | 91.13 |
Price Performance
Historical ComparisonAbout SGC Superior Group of Companies Inc.
Superior Group Of Companies Inc designs apparel products. The company's operating segment includes Branded Products; Healthcare Apparel and Contact Centers. It generates maximum revenue from the Branded Products segment. The Branded Products segment produce and sell customized merchandising solutions, promotional products and branded uniform programs to customers.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.